Compare Supplements

Approved regimen (Tymlos): 80 µg once daily by subcutaneous injection (abdomen), via a metered prefilled pen. This is a prescription drug — dose, duration and monitoring are set by a prescriber. The original 2-year cumulative-lifetime-use limit was REMOVED from the US label in 2021; duration is now an individualized clinical decision. There is no validated use outside osteoporosis fracture prevention.

Any time

Tymlos prefilled injector pen (prescription, via a clinician)

Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)

Any time

Once-weekly subcutaneous injection (Mounjaro / Zepbound)

• Conditions with increased baseline osteosarcoma risk — Paget's disease of bone, unexplained elevated alkaline phosphatase, prior external-beam or implant skeletal radiation, open epiphyses (pediatric/young-adult), or bone metastases / skeletal malignancy
• Pre-existing hypercalcemia or conditions predisposing to hypercalcemia
• Pregnancy and breastfeeding (not for use)

• Digoxin
• Antihypertensives / drugs causing orthostatic hypotension
• Other PTH1-receptor agonists (teriparatide) and other anabolic agents

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• History of pancreatitis (use with caution / avoid)

• Oral contraceptives
• Insulin and sulfonylureas
• Oral medications generally